Stress-test asset valuation before you deploy capital.

The Hidden Flaw in Scientific Valuations

Many life science investments look exceptional on paper when evaluated purely through a scientific lens. However, multi-billion-dollar asset valuations frequently collapse during the transition to the market because the underlying clinical trial architecture was fundamentally misaligned with global payer expectations.

Common, critical design flaws include selecting the wrong comparator arm, insufficient study duration or a patient population that does not align with the commercial forecast in pivotal trials. While a trial may achieve statistical significance against a placebo or an outdated standard of care, it will completely fail to support your target price or patient population when facing scrutiny by HTA agencies and payers.

Trials purely designed to meet regulatory requirements introduce structural vulnerabilities that can entirely derail the payer conversation. Without a strategic catalyst to spot these flaws early, investors risk backing a clinical success that is destined for commercial containment.

Core Due Diligence Offerings

• 1. Comparator & Trial Design Auditing
  • I independently audit target asset clinical protocols to ensure study endpoints and control arms match the evidence requirements of global HTA bodies and payers.
• 2. Pricing & Access Stress-Testing
  • I pressure-test proposed revenue models against international pricing benchmarks and strict global reimbursement realities to see if your valuation holds up to management and board scrutiny.
• 3. Incorporating Political Realities
  • Understanding the influence of political risks and regulatory frameworks on the viability of your business case enables more realistic assessments and can identify opportunities to optimize an asset's value through policy shaping.
• 4. Portfolio De-risking & Exit Readiness
  • I help existing portfolio companies correct course early, restructuring their value narratives so the asset actively demonstrates payer-relevant value before out-licensing or acquisition.